MedTrace Logo

Non-Interventional Open Label Prospective Observational Comparative Study On Evaluation Of Compliance Of The Empiric Treatment With Azithromycin SR Versus Amoxiclav 1000 Mg In Adult Patients With Mild To Moderate Community Acquired Pneumonia

NCT01032694 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2011-12-21

Study results available
· View outcomes & findings →

Summary

To compare compliance between patients with CAP treated with Azithromycin SR 2.0 g single dose orally and those treated with Amoxiclav - 1000 mg twice daily 10 days for the empiric treatment of CAP in outpatient clinic practice.

Conditions

  • Community-Acquired Pneumonia

Interventions

DRUG

Azithromycin SR

Azithromycin SR, 2.0 g PO x 1 dose for treatment period

DRUG

Amoxiclav

Amoxiclav 1000 x twice daily, 10 days duration

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2010-12-31
Completion
2010-12-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01032694 on ClinicalTrials.gov